Carol Aghajanian

Oct 11, 2024 | digitalcommons.library.tmc.edu | Vicky Makker |Matthew Taylor |Carol Aghajanian |Allen L. Cohn

BACKGROUND: Lenvatinib plus pembrolizumab demonstrated clinically meaningful benefit in patients with previously treated advanced endometrial carcinoma in Study 111/KEYNOTE-146 (NCT02501096). In these exploratory analyses from this study, we evaluated the associations between clinical outcomes and gene expression signature scores and descriptively summarized response in biomarker subpopulations defined by tumor mutational burden (TMB) and DNA variants for individual genes of interest.

Jan 1, 2024 | jitc.bmj.com | Vicky Makker |Matthew Taylor |Carol Aghajanian |Allen L. Cohn

Clinical/translational cancer immunotherapy Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146 Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service.